JP5876031B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP5876031B2 JP5876031B2 JP2013501421A JP2013501421A JP5876031B2 JP 5876031 B2 JP5876031 B2 JP 5876031B2 JP 2013501421 A JP2013501421 A JP 2013501421A JP 2013501421 A JP2013501421 A JP 2013501421A JP 5876031 B2 JP5876031 B2 JP 5876031B2
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- indol
- amine
- acetyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 175
- -1 —OH Chemical group 0.000 claims description 243
- 125000000217 alkyl group Chemical group 0.000 claims description 124
- 206010028980 Neoplasm Diseases 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 73
- 201000011510 cancer Diseases 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 36
- 125000001153 fluoro group Chemical group F* 0.000 claims description 31
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 150000001412 amines Chemical class 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 229960004979 fampridine Drugs 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 229940034982 antineoplastic agent Drugs 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- LCRXWSJBFYHPTM-UHFFFAOYSA-N 1-[5-(4-amino-7-piperidin-4-ylthieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C1CCNCC1 LCRXWSJBFYHPTM-UHFFFAOYSA-N 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 230000006793 arrhythmia Effects 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- GKFHWUKPJAYDMA-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1F GKFHWUKPJAYDMA-UHFFFAOYSA-N 0.000 claims description 5
- IJDWVHBBYQCFIF-UHFFFAOYSA-N 1-[5-(4-amino-7-pyridin-4-ylthieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C1=CC=NC=C1 IJDWVHBBYQCFIF-UHFFFAOYSA-N 0.000 claims description 5
- YGJZRPGTTACELL-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,3-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(F)=C1F YGJZRPGTTACELL-UHFFFAOYSA-N 0.000 claims description 5
- YIEAFENYFHZFJZ-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 YIEAFENYFHZFJZ-UHFFFAOYSA-N 0.000 claims description 5
- GIDAHXRLHKZRNS-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-naphthalen-1-ylethanone Chemical compound C1=CC=C2C(CC(=O)N3C4=CC=C(C=C4CC3)C3=CSC=4C=CN=C(C3=4)N)=CC=CC2=C1 GIDAHXRLHKZRNS-UHFFFAOYSA-N 0.000 claims description 5
- ZDMNFWRMUCKWCS-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1 ZDMNFWRMUCKWCS-UHFFFAOYSA-N 0.000 claims description 5
- ALATVONJVIWCTN-UHFFFAOYSA-N 1-[5-[4-amino-7-(1,2,3,6-tetrahydropyridin-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C1=CCNCC1 ALATVONJVIWCTN-UHFFFAOYSA-N 0.000 claims description 5
- LIGGMBSSOOVGAE-UHFFFAOYSA-N 1-[5-[4-amino-7-(1-methylpyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=NN(C)C=C1C1=CN=C(N)C2=C1SC=C2C1=CC=C(N(CC2)C(=O)CC=3C=CC=CC=3)C2=C1 LIGGMBSSOOVGAE-UHFFFAOYSA-N 0.000 claims description 5
- LNIIQYCRVCPHRI-UHFFFAOYSA-N 1-[5-[4-amino-7-(1h-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2OC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C(=CC=C(F)C=3)F)C=2C(N)=NC=C1C=1C=NNC=1 LNIIQYCRVCPHRI-UHFFFAOYSA-N 0.000 claims description 5
- MDFBUIJAQZTAER-UHFFFAOYSA-N 3-[2-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-oxoethyl]benzonitrile Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C#N)=C1 MDFBUIJAQZTAER-UHFFFAOYSA-N 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000010230 macular retinal edema Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- LTBUGKMPWQPUFH-UHFFFAOYSA-N 1-[5-(3-amino-1-methylindazol-4-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C=3C(N)=NN(C)C=3C=CC=2)=C1 LTBUGKMPWQPUFH-UHFFFAOYSA-N 0.000 claims description 4
- SESFBYNEOGDFFU-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,3,5-trifluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(F)=C1F SESFBYNEOGDFFU-UHFFFAOYSA-N 0.000 claims description 4
- GIZWNTWUPYQIIB-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-chlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1Cl GIZWNTWUPYQIIB-UHFFFAOYSA-N 0.000 claims description 4
- WBJCGEANTKDMIV-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC=C(F)C(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 WBJCGEANTKDMIV-UHFFFAOYSA-N 0.000 claims description 4
- XFEKDKLXPRFQSI-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dichlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(Cl)=CC(Cl)=C1 XFEKDKLXPRFQSI-UHFFFAOYSA-N 0.000 claims description 4
- RLKXVMKDLQLMED-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC(F)=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 RLKXVMKDLQLMED-UHFFFAOYSA-N 0.000 claims description 4
- ZESKLTGPCIXLID-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 ZESKLTGPCIXLID-UHFFFAOYSA-N 0.000 claims description 4
- BINOXKRRZHTPDH-UHFFFAOYSA-N 1-[5-(4-amino-2h-pyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2C(N)=NC=NC=2NN=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1 BINOXKRRZHTPDH-UHFFFAOYSA-N 0.000 claims description 4
- AMQHYFMNSQHFAH-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 AMQHYFMNSQHFAH-UHFFFAOYSA-N 0.000 claims description 4
- VTNFUMDFHIHAHA-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1 VTNFUMDFHIHAHA-UHFFFAOYSA-N 0.000 claims description 4
- XSKKJZREOBORCM-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F XSKKJZREOBORCM-UHFFFAOYSA-N 0.000 claims description 4
- YDRLBYPQASBCQA-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F YDRLBYPQASBCQA-UHFFFAOYSA-N 0.000 claims description 4
- HLXXZZJOWXVYFE-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-chlorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1Cl HLXXZZJOWXVYFE-UHFFFAOYSA-N 0.000 claims description 4
- RYVFTJZSAOBQNH-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-methoxyphenyl)ethanone Chemical compound COC1=CC=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CC=C4SC=3)C=C2CC1 RYVFTJZSAOBQNH-UHFFFAOYSA-N 0.000 claims description 4
- OKLWDHFBKQJSFD-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chlorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1 OKLWDHFBKQJSFD-UHFFFAOYSA-N 0.000 claims description 4
- ADXYXPNGWRZFOH-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-2-methylphenyl)ethanone Chemical compound CC1=C(F)C=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CC=C4SC=3)C=C2CC1 ADXYXPNGWRZFOH-UHFFFAOYSA-N 0.000 claims description 4
- YQMAMHOIVLBXCV-UHFFFAOYSA-N 1-[5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CC=C3SC=2)=C1 YQMAMHOIVLBXCV-UHFFFAOYSA-N 0.000 claims description 4
- NXZHFEXEUNSRPZ-UHFFFAOYSA-N 1-[5-[4-amino-7-(1h-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C=1C=NNC=1 NXZHFEXEUNSRPZ-UHFFFAOYSA-N 0.000 claims description 4
- DMKVBTQRZDFRLH-UHFFFAOYSA-N 1-[5-[4-amino-7-(1h-pyrazol-5-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C(=CC=C(F)C=3)F)C=2C(N)=NC=C1C=1C=CNN=1 DMKVBTQRZDFRLH-UHFFFAOYSA-N 0.000 claims description 4
- KZBTXUJVLZUTCP-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-morpholin-4-ylethyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C(=CC=C(F)C=2)F)C=2C(N)=NC=NC=2N1CCN1CCOCC1 KZBTXUJVLZUTCP-UHFFFAOYSA-N 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- SIXVRXARNAVBTC-UHFFFAOYSA-N gsk2606414 Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 SIXVRXARNAVBTC-UHFFFAOYSA-N 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- DVZUNDFNVGOMIR-UHFFFAOYSA-N 1-[5-(3-amino-1-methylindazol-4-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=CC=C2N(C)N=C(N)C2=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F DVZUNDFNVGOMIR-UHFFFAOYSA-N 0.000 claims description 3
- VVBQWWMXMCDPEG-UHFFFAOYSA-N 1-[5-(4-amino-1-ethylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(CC)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C)=C1 VVBQWWMXMCDPEG-UHFFFAOYSA-N 0.000 claims description 3
- YAXYZIOTZHOMJR-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(1-methylpyrrol-2-yl)ethanone Chemical compound CN1C=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)N=3)C=C2CC1 YAXYZIOTZHOMJR-UHFFFAOYSA-N 0.000 claims description 3
- TZXSSKXQPFWREE-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,3-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(F)=C1F TZXSSKXQPFWREE-UHFFFAOYSA-N 0.000 claims description 3
- NGJPFYYMTFFFQD-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,3-dimethylphenyl)ethanone Chemical class CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1C NGJPFYYMTFFFQD-UHFFFAOYSA-N 0.000 claims description 3
- MOGOTLONLODTPO-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F MOGOTLONLODTPO-UHFFFAOYSA-N 0.000 claims description 3
- CDYXNHLXTXSSEX-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-dimethylphenyl)ethanone Chemical class CC1=CC=C(C)C(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 CDYXNHLXTXSSEX-UHFFFAOYSA-N 0.000 claims description 3
- ZQWKJTUXQVOHRU-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-fluoro-3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1F ZQWKJTUXQVOHRU-UHFFFAOYSA-N 0.000 claims description 3
- RPYWMTAZIHYVCQ-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-methylphenyl)ethanone Chemical compound CC1=CC=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)N=3)C=C2CC1 RPYWMTAZIHYVCQ-UHFFFAOYSA-N 0.000 claims description 3
- HNPFHOGITDHNIB-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3,5-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(F)=C1 HNPFHOGITDHNIB-UHFFFAOYSA-N 0.000 claims description 3
- JJFROWMYMXTNRW-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dimethylphenyl)ethanone Chemical class CC1=CC(C)=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 JJFROWMYMXTNRW-UHFFFAOYSA-N 0.000 claims description 3
- OBQVMGVZZDJESR-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-2-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1F OBQVMGVZZDJESR-UHFFFAOYSA-N 0.000 claims description 3
- QRAKFAYRIYRKKQ-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-4-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(Cl)=C1 QRAKFAYRIYRKKQ-UHFFFAOYSA-N 0.000 claims description 3
- CGXQXGFKDSOTFZ-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1 CGXQXGFKDSOTFZ-UHFFFAOYSA-N 0.000 claims description 3
- ITSYETRIUIKPCI-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-2-methylphenyl)ethanone Chemical compound CC1=C(F)C=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)N=3)C=C2CC1 ITSYETRIUIKPCI-UHFFFAOYSA-N 0.000 claims description 3
- WUVMRQNYFNAOGE-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(F)=C1 WUVMRQNYFNAOGE-UHFFFAOYSA-N 0.000 claims description 3
- YBYFZQXTSQRQSG-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 YBYFZQXTSQRQSG-UHFFFAOYSA-N 0.000 claims description 3
- FSTWIINKQYTMQD-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1 FSTWIINKQYTMQD-UHFFFAOYSA-N 0.000 claims description 3
- MEYQSOXIDZBADD-UHFFFAOYSA-N 1-[5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F MEYQSOXIDZBADD-UHFFFAOYSA-N 0.000 claims description 3
- AZRWIVSDCCXMCP-UHFFFAOYSA-N 1-[5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C)=C1 AZRWIVSDCCXMCP-UHFFFAOYSA-N 0.000 claims description 3
- JFAUHPNCLGOGQC-UHFFFAOYSA-N 1-[5-(4-amino-7-methylfuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C=1OC=2C(C)=CN=C(N)C=2C=1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F JFAUHPNCLGOGQC-UHFFFAOYSA-N 0.000 claims description 3
- BIXINRQAPNCTIE-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(1-methylpyrrol-2-yl)ethanone Chemical compound CN1C=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 BIXINRQAPNCTIE-UHFFFAOYSA-N 0.000 claims description 3
- IDBYHPSFUAYUAW-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-dimethylphenyl)ethanone Chemical class CC1=CC=C(C)C(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 IDBYHPSFUAYUAW-UHFFFAOYSA-N 0.000 claims description 3
- OTGQMOPRPFKJKL-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-chlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1Cl OTGQMOPRPFKJKL-UHFFFAOYSA-N 0.000 claims description 3
- YQUIIWKHVCZVMZ-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1F YQUIIWKHVCZVMZ-UHFFFAOYSA-N 0.000 claims description 3
- GRMYYXQYYMKJDL-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3,5-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(F)=C1 GRMYYXQYYMKJDL-UHFFFAOYSA-N 0.000 claims description 3
- UYDKBGHYPDVNKT-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-2,4-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(Cl)=C1F UYDKBGHYPDVNKT-UHFFFAOYSA-N 0.000 claims description 3
- XPMJPEXKYOIRLX-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-5-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(Cl)=C1 XPMJPEXKYOIRLX-UHFFFAOYSA-N 0.000 claims description 3
- KWZXRCBCAYLKPI-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1 KWZXRCBCAYLKPI-UHFFFAOYSA-N 0.000 claims description 3
- WBSMPJAMWXVOCW-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC(F)=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 WBSMPJAMWXVOCW-UHFFFAOYSA-N 0.000 claims description 3
- IUQGBQGTWOTQOS-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(F)=C1 IUQGBQGTWOTQOS-UHFFFAOYSA-N 0.000 claims description 3
- PXVQGBJMIQCDEX-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(C(F)(F)F)=C1 PXVQGBJMIQCDEX-UHFFFAOYSA-N 0.000 claims description 3
- FSNLTBKFTVCBGX-UHFFFAOYSA-N 1-[5-(4-amino-7-piperidin-4-ylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2N(C2CCNCC2)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F FSNLTBKFTVCBGX-UHFFFAOYSA-N 0.000 claims description 3
- VNDDOAWIHYNTOI-UHFFFAOYSA-N 1-[5-(4-amino-7-pyridin-3-ylthieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C1=CC=CN=C1 VNDDOAWIHYNTOI-UHFFFAOYSA-N 0.000 claims description 3
- VAMLDTHVKNLBIL-UHFFFAOYSA-N 1-[5-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F VAMLDTHVKNLBIL-UHFFFAOYSA-N 0.000 claims description 3
- ADHLFPDHHCLCSS-UHFFFAOYSA-N 1-[5-[4-amino-1-(2-hydroxyethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(CCO)N=2)=C1 ADHLFPDHHCLCSS-UHFFFAOYSA-N 0.000 claims description 3
- DIPVTLUPQWHTMP-UHFFFAOYSA-N 1-[5-[4-amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1CN(C)CCC1N1C2=NC=NC(N)=C2C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C(=CC=C(F)C=2)F)=C1 DIPVTLUPQWHTMP-UHFFFAOYSA-N 0.000 claims description 3
- MWELMYBBSKNFGX-UHFFFAOYSA-N 1-[5-[4-amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound C1CN(C)CCC1N1C2=NC=NC(N)=C2C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=C(C)C=CC=2)=C1 MWELMYBBSKNFGX-UHFFFAOYSA-N 0.000 claims description 3
- HJJRKPDBOXPHEC-UHFFFAOYSA-N 1-[5-[4-amino-7-(1h-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C(=CC=C(F)C=3)F)C=2C(N)=NC=C1C=1C=NNC=1 HJJRKPDBOXPHEC-UHFFFAOYSA-N 0.000 claims description 3
- KBDRRJHDGVRGEZ-UHFFFAOYSA-N 1-[5-[4-amino-7-(azetidin-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C3CNC3)C=2)=C1 KBDRRJHDGVRGEZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 201000002847 Cowden syndrome Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010018404 Glucagonoma Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 208000006336 acinar cell carcinoma Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 210000002987 choroid plexus Anatomy 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 206010022498 insulinoma Diseases 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- XXIKKKQUZADDJI-UHFFFAOYSA-N 1-[5-(3-amino-1-methylpyrazolo[3,4-c]pyridin-4-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=NC=C2N(C)N=C(N)C2=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 XXIKKKQUZADDJI-UHFFFAOYSA-N 0.000 claims description 2
- FYILOGFFIMZZHN-UHFFFAOYSA-N 1-[5-(3-amino-1h-pyrazolo[3,4-c]pyridin-4-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C=3C(N)=NNC=3C=NC=2)=C1 FYILOGFFIMZZHN-UHFFFAOYSA-N 0.000 claims description 2
- DYBQYHYWCJCVLA-UHFFFAOYSA-N 1-[5-(3-amino-1h-pyrazolo[3,4-c]pyridin-4-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C=12C(N)=NNC2=CN=CC=1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 DYBQYHYWCJCVLA-UHFFFAOYSA-N 0.000 claims description 2
- HZRAUJCNKKOMSA-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dimethylpyrazol-1-yl)ethanone Chemical compound N1=C(C)C=C(C)N1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)N=3)C=C2CC1 HZRAUJCNKKOMSA-UHFFFAOYSA-N 0.000 claims description 2
- OYIQCCHZASPGKV-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-2,4-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)N=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(Cl)=C1F OYIQCCHZASPGKV-UHFFFAOYSA-N 0.000 claims description 2
- VFMMINQECOXKJE-UHFFFAOYSA-N 1-[5-(4-amino-7-chlorofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=C(Cl)C=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F VFMMINQECOXKJE-UHFFFAOYSA-N 0.000 claims description 2
- JCUSVFKWUQBVHH-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,3,5-trifluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(F)=C1F JCUSVFKWUQBVHH-UHFFFAOYSA-N 0.000 claims description 2
- VJSIBHLNZILMMB-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,3-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(F)=C1F VJSIBHLNZILMMB-UHFFFAOYSA-N 0.000 claims description 2
- DERZGVXEDJHCSM-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,3-dimethylphenyl)ethanone Chemical class CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1C DERZGVXEDJHCSM-UHFFFAOYSA-N 0.000 claims description 2
- ASBCVDJDVCPJPN-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,4-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C=C1F ASBCVDJDVCPJPN-UHFFFAOYSA-N 0.000 claims description 2
- NAVYMHNQQHXBIP-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F NAVYMHNQQHXBIP-UHFFFAOYSA-N 0.000 claims description 2
- OPBOPTNNBUGVFI-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-fluoro-3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1F OPBOPTNNBUGVFI-UHFFFAOYSA-N 0.000 claims description 2
- PXKYXXQLSPOLIS-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC=C(F)C(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 PXKYXXQLSPOLIS-UHFFFAOYSA-N 0.000 claims description 2
- GUYCUWKVWVPERE-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3,4-difluorophenyl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(F)=C1 GUYCUWKVWVPERE-UHFFFAOYSA-N 0.000 claims description 2
- HJEAKDREZJGIDT-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dichlorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(Cl)=CC(Cl)=C1 HJEAKDREZJGIDT-UHFFFAOYSA-N 0.000 claims description 2
- YOSIQNWSKDRHSN-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dimethylphenyl)ethanone Chemical class CC1=CC(C)=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 YOSIQNWSKDRHSN-UHFFFAOYSA-N 0.000 claims description 2
- YOPJEHCJCZXQQN-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3,5-dimethylpyrazol-1-yl)ethanone Chemical compound N1=C(C)C=C(C)N1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 YOPJEHCJCZXQQN-UHFFFAOYSA-N 0.000 claims description 2
- SYRMSMDEKJBWHP-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-2-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1F SYRMSMDEKJBWHP-UHFFFAOYSA-N 0.000 claims description 2
- USTMPLNJDHASCE-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-4-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(Cl)=C1 USTMPLNJDHASCE-UHFFFAOYSA-N 0.000 claims description 2
- TZCLXAAXHYTHFQ-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-2-methylphenyl)ethanone Chemical compound CC1=C(F)C=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 TZCLXAAXHYTHFQ-UHFFFAOYSA-N 0.000 claims description 2
- UPZRHWRFZZDQOR-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(5-chloro-2-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(Cl)=CC=C1F UPZRHWRFZZDQOR-UHFFFAOYSA-N 0.000 claims description 2
- PPJWJOYOOLVOPL-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[6-(trifluoromethyl)pyridin-2-yl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=N1 PPJWJOYOOLVOPL-UHFFFAOYSA-N 0.000 claims description 2
- QAQGADSQUHQENU-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(1-methylpyrrol-2-yl)ethanone Chemical compound CN1C=CC=C1CC(=O)N1C(C=CC(C=2C3=C(N)N=CN=C3N(C)C=2)=C2F)=C2CC1 QAQGADSQUHQENU-UHFFFAOYSA-N 0.000 claims description 2
- WXXUBTSRNAELLN-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F WXXUBTSRNAELLN-UHFFFAOYSA-N 0.000 claims description 2
- HFOKVVVCWLIUBP-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(3,5-dimethylpyrazol-1-yl)ethanone Chemical compound N1=C(C)C=C(C)N1CC(=O)N1C(C=CC(C=2C3=C(N)N=CN=C3N(C)C=2)=C2F)=C2CC1 HFOKVVVCWLIUBP-UHFFFAOYSA-N 0.000 claims description 2
- SVGSTQQZIWQJIP-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC=C(F)C=C1 SVGSTQQZIWQJIP-UHFFFAOYSA-N 0.000 claims description 2
- OXCDELRTBMVGGJ-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 OXCDELRTBMVGGJ-UHFFFAOYSA-N 0.000 claims description 2
- OHQLJGNVBBJKJM-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 OHQLJGNVBBJKJM-UHFFFAOYSA-N 0.000 claims description 2
- QAEKSWBVYBVLNO-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-[6-(trifluoromethyl)pyridin-2-yl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=N1 QAEKSWBVYBVLNO-UHFFFAOYSA-N 0.000 claims description 2
- WFRSIDBMPCGUCM-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC=CC=C1 WFRSIDBMPCGUCM-UHFFFAOYSA-N 0.000 claims description 2
- DVXFAMNAPVVGJH-UHFFFAOYSA-N 1-[5-(4-amino-7-piperidin-4-ylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C3CCNCC3)C=2)=C1 DVXFAMNAPVVGJH-UHFFFAOYSA-N 0.000 claims description 2
- ZFAPCMHDMUSNAZ-UHFFFAOYSA-N 1-[5-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F ZFAPCMHDMUSNAZ-UHFFFAOYSA-N 0.000 claims description 2
- MHKWNFPMMUEEAB-UHFFFAOYSA-N 1-[5-(4-amino-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 MHKWNFPMMUEEAB-UHFFFAOYSA-N 0.000 claims description 2
- UKHCCSNWBRFVPU-UHFFFAOYSA-N 1-[5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CNC2=NC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 UKHCCSNWBRFVPU-UHFFFAOYSA-N 0.000 claims description 2
- VODMNNHLALPLST-UHFFFAOYSA-N 1-[5-(4-aminofuro[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F VODMNNHLALPLST-UHFFFAOYSA-N 0.000 claims description 2
- XOORPXAGLUZPHS-UHFFFAOYSA-N 1-[5-(4-aminofuro[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-5-fluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(Cl)=C1 XOORPXAGLUZPHS-UHFFFAOYSA-N 0.000 claims description 2
- UUGZZQOOGXFAGK-UHFFFAOYSA-N 1-[5-(4-aminofuro[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3OC=2)=C1 UUGZZQOOGXFAGK-UHFFFAOYSA-N 0.000 claims description 2
- YJSYFAZNZDCIRA-UHFFFAOYSA-N 1-[5-(4-aminofuro[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=2C(N)=NC=NC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 YJSYFAZNZDCIRA-UHFFFAOYSA-N 0.000 claims description 2
- CVEBHQXUXFPRJM-UHFFFAOYSA-N 1-[5-(4-aminofuro[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone Chemical compound C1=2C(N)=NC=NC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(C(F)(F)F)=C1 CVEBHQXUXFPRJM-UHFFFAOYSA-N 0.000 claims description 2
- DGNADWRFRUUBFT-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC=C(F)C(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CC=C3OC=2)=C1 DGNADWRFRUUBFT-UHFFFAOYSA-N 0.000 claims description 2
- SMLPGAUCABNACE-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chloro-5-fluorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC(Cl)=C1 SMLPGAUCABNACE-UHFFFAOYSA-N 0.000 claims description 2
- XJLNMANYLHSSPJ-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-chlorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=C1 XJLNMANYLHSSPJ-UHFFFAOYSA-N 0.000 claims description 2
- QFBGXDRWDZBXNG-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-fluoro-5-methylphenyl)ethanone Chemical compound CC1=CC(F)=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CC=C3OC=2)=C1 QFBGXDRWDZBXNG-UHFFFAOYSA-N 0.000 claims description 2
- UJTAMAPOTCQOBN-UHFFFAOYSA-N 1-[5-(4-aminofuro[3,2-c]pyridin-3-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=CC=2OC=C1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F UJTAMAPOTCQOBN-UHFFFAOYSA-N 0.000 claims description 2
- ARWFXUUHCPHWIT-UHFFFAOYSA-N 1-[5-[4-amino-7-(1-methylazetidin-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1N(C)CC1N1C2=NC=NC(N)=C2C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=C(C=CC=2)C(F)(F)F)=C1 ARWFXUUHCPHWIT-UHFFFAOYSA-N 0.000 claims description 2
- HCUCAPVCKVLDAV-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-aminoethyl)furo[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C=1OC=2C(CCN)=CN=C(N)C=2C=1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F HCUCAPVCKVLDAV-UHFFFAOYSA-N 0.000 claims description 2
- XMBIODIDIVSHCA-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-aminoethyl)furo[3,2-c]pyridin-3-yl]-4-fluoro-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C=1OC=2C(CCN)=CN=C(N)C=2C=1C(C(=C1CC2)F)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F XMBIODIDIVSHCA-UHFFFAOYSA-N 0.000 claims description 2
- WNNGUYJJXYQOQW-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-morpholin-4-ylethyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=C(C=CC=2)C(F)(F)F)C=2C(N)=NC=NC=2N1CCN1CCOCC1 WNNGUYJJXYQOQW-UHFFFAOYSA-N 0.000 claims description 2
- VORWOQANXIBYOJ-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-piperidin-4-ylethyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C(=CC=C(F)C=2)F)C=2C(N)=NC=NC=2N1CCC1CCNCC1 VORWOQANXIBYOJ-UHFFFAOYSA-N 0.000 claims description 2
- GSZVIVBLSQUDIH-UHFFFAOYSA-N 1-[5-[4-amino-7-(2-piperidin-4-ylethyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=C(C=CC=2)C(F)(F)F)C=2C(N)=NC=NC=2N1CCC1CCNCC1 GSZVIVBLSQUDIH-UHFFFAOYSA-N 0.000 claims description 2
- QYNKYSGKDXHTAZ-UHFFFAOYSA-N 1-[5-[4-amino-7-(3-methylbutyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(CCC(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F QYNKYSGKDXHTAZ-UHFFFAOYSA-N 0.000 claims description 2
- SRANPKCPKWERBD-UHFFFAOYSA-N 1-[5-[4-amino-7-(3-methylbutyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(CCC(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 SRANPKCPKWERBD-UHFFFAOYSA-N 0.000 claims description 2
- GVLXFVFBZOBDSY-UHFFFAOYSA-N 1-[5-[4-amino-7-(azetidin-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2N(C2CNC2)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F GVLXFVFBZOBDSY-UHFFFAOYSA-N 0.000 claims description 2
- GENILDDQSUOWFO-UHFFFAOYSA-N 1-[5-[4-amino-7-(azetidin-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=2C(N)=NC=NC=2N(C2CNC2)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 GENILDDQSUOWFO-UHFFFAOYSA-N 0.000 claims description 2
- LXCSXKNDQGKWEN-UHFFFAOYSA-N 1-[5-[4-amino-7-(methoxymethyl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(COC)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C)=C1 LXCSXKNDQGKWEN-UHFFFAOYSA-N 0.000 claims description 2
- YVMAUFWIRAIYAX-UHFFFAOYSA-N 1-[5-[4-amino-7-(oxetan-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C1=2C(N)=NC=NC=2N(C2COC2)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 YVMAUFWIRAIYAX-UHFFFAOYSA-N 0.000 claims description 2
- FCCYRLBLEOKTHL-UHFFFAOYSA-N 1-[5-[4-amino-7-[2-(dimethylamino)ethyl]furo[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C=1OC=2C(CCN(C)C)=CN=C(N)C=2C=1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F FCCYRLBLEOKTHL-UHFFFAOYSA-N 0.000 claims description 2
- PKLANCAXYPOSFE-UHFFFAOYSA-N 1-[5-[4-amino-7-[2-(dimethylamino)ethyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(CCN(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F PKLANCAXYPOSFE-UHFFFAOYSA-N 0.000 claims description 2
- ORZGWTRZIQKNCG-UHFFFAOYSA-N 1-[5-[4-amino-7-[2-(dimethylamino)ethyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(CCN(C)C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 ORZGWTRZIQKNCG-UHFFFAOYSA-N 0.000 claims description 2
- JHTCJQBBGIUBMH-UHFFFAOYSA-N 4-amino-3-[1-[2-(2,5-difluorophenyl)acetyl]-2,3-dihydroindol-5-yl]furo[3,2-c]pyridine-7-carbonitrile Chemical compound C1=2C(N)=NC=C(C#N)C=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F JHTCJQBBGIUBMH-UHFFFAOYSA-N 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000014882 Carotid artery disease Diseases 0.000 claims description 2
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- PRWSIEBRGXYXAJ-UHFFFAOYSA-N GSK2656157 Chemical compound CC1=CC=CC(CC(=O)N2C3=C(C(=C(C=4C5=C(N)N=CN=C5N(C)C=4)C=C3)F)CC2)=N1 PRWSIEBRGXYXAJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 2
- 206010022941 Iridocyclitis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 108091008010 PERKs Proteins 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 201000002154 Pterygium Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 2
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims description 2
- 201000004612 anterior uveitis Diseases 0.000 claims description 2
- 201000011143 bone giant cell tumor Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000036260 idiopathic disease Diseases 0.000 claims description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 208000014081 polyp of colon Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- RHJIUZMDTSMYFE-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-methylphenyl)ethanone Chemical compound CC1=CC=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 RHJIUZMDTSMYFE-UHFFFAOYSA-N 0.000 claims 1
- GLWXZSGYBQBVEI-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(4-fluorophenyl)ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C=C1 GLWXZSGYBQBVEI-UHFFFAOYSA-N 0.000 claims 1
- FMTSZHILRVCVSZ-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 FMTSZHILRVCVSZ-UHFFFAOYSA-N 0.000 claims 1
- YFVHPOTWZXFDIV-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-chloro-2,3-dihydroindol-1-yl]-2-(6-methylpyridin-2-yl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=C(C(=C(C=4C5=C(N)N=CN=C5N(C)C=4)C=C3)Cl)CC2)=N1 YFVHPOTWZXFDIV-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- OITOVTXVPJUAMY-UHFFFAOYSA-N ClC1=C2CCN(C2=CC=C1C=1N=C(C2=C(N=1)N(C=C2)C)N)C(CC1=NC(=CC=C1)C(F)(F)F)=O Chemical compound ClC1=C2CCN(C2=CC=C1C=1N=C(C2=C(N=1)N(C=C2)C)N)C(CC1=NC(=CC=C1)C(F)(F)F)=O OITOVTXVPJUAMY-UHFFFAOYSA-N 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 295
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 270
- 239000007787 solid Substances 0.000 description 269
- 239000000203 mixture Substances 0.000 description 209
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 207
- 238000006243 chemical reaction Methods 0.000 description 182
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 158
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 154
- 235000019439 ethyl acetate Nutrition 0.000 description 139
- 238000005481 NMR spectroscopy Methods 0.000 description 114
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 100
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 93
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 86
- 239000007821 HATU Substances 0.000 description 75
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 67
- 239000000047 product Substances 0.000 description 65
- 235000002639 sodium chloride Nutrition 0.000 description 58
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 56
- 238000011282 treatment Methods 0.000 description 51
- 239000003112 inhibitor Substances 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 40
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- 239000012267 brine Substances 0.000 description 28
- 238000003818 flash chromatography Methods 0.000 description 28
- 229920006395 saturated elastomer Polymers 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 27
- 239000012071 phase Substances 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 229910002666 PdCl2 Inorganic materials 0.000 description 23
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 125000003282 alkyl amino group Chemical group 0.000 description 21
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 21
- 230000000670 limiting effect Effects 0.000 description 21
- 230000004906 unfolded protein response Effects 0.000 description 21
- 206010065553 Bone marrow failure Diseases 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 108091000080 Phosphotransferase Proteins 0.000 description 18
- 102000020233 phosphotransferase Human genes 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 125000000753 cycloalkyl group Chemical group 0.000 description 16
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- 230000022131 cell cycle Effects 0.000 description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- 229910052681 coesite Inorganic materials 0.000 description 14
- 229910052906 cristobalite Inorganic materials 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 235000012239 silicon dioxide Nutrition 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 229910052682 stishovite Inorganic materials 0.000 description 14
- 229910052905 tridymite Inorganic materials 0.000 description 14
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 13
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 235000011114 ammonium hydroxide Nutrition 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 229940102223 injectable solution Drugs 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 12
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- ZTMNZMFTINAOTM-UHFFFAOYSA-N 3-(2,3-dihydro-1h-indol-5-yl)-1-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C)N=C1C1=CC=C(NCC2)C2=C1 ZTMNZMFTINAOTM-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 10
- 229940127089 cytotoxic agent Drugs 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000035882 stress Effects 0.000 description 10
- IJLYCYZDONMWHG-UHFFFAOYSA-N 3-(2,3-dihydro-1h-indol-5-yl)thieno[3,2-c]pyridin-4-amine Chemical compound C1=C2NCCC2=CC(C2=CSC=3C=CN=C(C2=3)N)=C1 IJLYCYZDONMWHG-UHFFFAOYSA-N 0.000 description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 235000011056 potassium acetate Nutrition 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 108010092160 Dactinomycin Proteins 0.000 description 7
- 102000009465 Growth Factor Receptors Human genes 0.000 description 7
- 108010009202 Growth Factor Receptors Proteins 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical class C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 229940123090 PERK inhibitor Drugs 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 7
- LIVYKAHFQBZQRL-UHFFFAOYSA-N thieno[3,2-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1C=CS2 LIVYKAHFQBZQRL-UHFFFAOYSA-N 0.000 description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 6
- 229940122803 Vinca alkaloid Drugs 0.000 description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
- 239000000908 ammonium hydroxide Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000005587 bubbling Effects 0.000 description 6
- 229940127093 camptothecin Drugs 0.000 description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
- 229960004316 cisplatin Drugs 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 150000004141 diterpene derivatives Chemical class 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 6
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 5
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 5
- 229940079156 Proteasome inhibitor Drugs 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 229960000640 dactinomycin Drugs 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229960001428 mercaptopurine Drugs 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 239000003207 proteasome inhibitor Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229960001278 teniposide Drugs 0.000 description 5
- 150000003536 tetrazoles Chemical class 0.000 description 5
- 229960003087 tioguanine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960000303 topotecan Drugs 0.000 description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
- 229960004528 vincristine Drugs 0.000 description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- PJJOXYAISAQNQK-UHFFFAOYSA-N 1-[5-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=C(I)C=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F PJJOXYAISAQNQK-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 4
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 4
- CXRNQXFFWARLSJ-UHFFFAOYSA-N 5-(2,3-dihydro-1h-indol-5-yl)-7-methylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C)C=C1C1=CC=C(NCC2)C2=C1 CXRNQXFFWARLSJ-UHFFFAOYSA-N 0.000 description 4
- QEDCHCLHHGGYBT-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-indole Chemical compound BrC1=CC=C2NCCC2=C1 QEDCHCLHHGGYBT-UHFFFAOYSA-N 0.000 description 4
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 4
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 4
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 102000014400 SH2 domains Human genes 0.000 description 4
- 108050003452 SH2 domains Proteins 0.000 description 4
- 102000000395 SH3 domains Human genes 0.000 description 4
- 108050008861 SH3 domains Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 description 4
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 229960005243 carmustine Drugs 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229960004630 chlorambucil Drugs 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229960003901 dacarbazine Drugs 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002944 hormone and hormone analog Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- ACFATEXDOOPGOE-UHFFFAOYSA-N tert-butyl 4-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=NC=NC(N)=C2C(Br)=C1 ACFATEXDOOPGOE-UHFFFAOYSA-N 0.000 description 4
- OOORQXGLIKPNDK-UHFFFAOYSA-N tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)CCC2=CC=1B1OC(C)(C)C(C)(C)O1 OOORQXGLIKPNDK-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 4
- 229960002066 vinorelbine Drugs 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- VABCKUZSJTWHQV-UHFFFAOYSA-N 1-(5-bromo-2,3-dihydroindol-1-yl)-2-(2,5-difluorophenyl)ethanone Chemical compound FC1=CC=C(F)C(CC(=O)N2C3=CC=C(Br)C=C3CC2)=C1 VABCKUZSJTWHQV-UHFFFAOYSA-N 0.000 description 3
- AIGLAWLPBQKHPW-UHFFFAOYSA-N 1-[5-(4-amino-7-pyridin-3-ylthieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical class C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C(=CC=C(F)C=3)F)C=2C(N)=NC=C1C1=CC=CN=C1 AIGLAWLPBQKHPW-UHFFFAOYSA-N 0.000 description 3
- ODYPJFBAIADVRN-UHFFFAOYSA-N 1-[5-[4-amino-7-[3-[(dimethylamino)methyl]phenyl]thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical class CN(C)CC1=CC=CC(C=2C=3SC=C(C=3C(N)=NC=2)C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=CC=CC=2)=C1 ODYPJFBAIADVRN-UHFFFAOYSA-N 0.000 description 3
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 3
- UXSQXUSJGPVOKT-UHFFFAOYSA-N 2-(2,3-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1F UXSQXUSJGPVOKT-UHFFFAOYSA-N 0.000 description 3
- IUJAAIZKRJJZGQ-UHFFFAOYSA-N 2-(2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Cl IUJAAIZKRJJZGQ-UHFFFAOYSA-N 0.000 description 3
- CQFSSMCJXPLZAT-UHFFFAOYSA-N 2-(2-fluoro-5-methylphenyl)acetic acid Chemical compound CC1=CC=C(F)C(CC(O)=O)=C1 CQFSSMCJXPLZAT-UHFFFAOYSA-N 0.000 description 3
- IVEWTCACRDEAOB-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetic acid Chemical compound COC1=CC=CC=C1CC(O)=O IVEWTCACRDEAOB-UHFFFAOYSA-N 0.000 description 3
- ZAHVIROTQSRTEF-UHFFFAOYSA-N 2-(3-methylphenyl)-1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydroindol-1-yl]ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)B2OC(C)(C)C(C)(C)O2)=C1 ZAHVIROTQSRTEF-UHFFFAOYSA-N 0.000 description 3
- BLXXCCIBGGBDHI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1 BLXXCCIBGGBDHI-UHFFFAOYSA-N 0.000 description 3
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 3
- LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 3
- DHFYKLULHRGVSL-UHFFFAOYSA-N 3-bromo-1-methylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(C)N=C(Br)C2=C1N DHFYKLULHRGVSL-UHFFFAOYSA-N 0.000 description 3
- OZULUFUHMFFLQF-UHFFFAOYSA-N 3-iodo-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(C(C)C)N=C(I)C2=C1N OZULUFUHMFFLQF-UHFFFAOYSA-N 0.000 description 3
- GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 3
- OXLMTRZWMHIZBY-UHFFFAOYSA-N 5-bromo-4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(Br)=CN2 OXLMTRZWMHIZBY-UHFFFAOYSA-N 0.000 description 3
- QREZXKIMBVMLAK-UHFFFAOYSA-N 5-bromo-7-(2-morpholin-4-ylethyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=C(Br)C=2C(N)=NC=NC=2N1CCN1CCOCC1 QREZXKIMBVMLAK-UHFFFAOYSA-N 0.000 description 3
- SCHJLAFNBDGWJN-UHFFFAOYSA-N 5-bromo-7-methylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(C)C=C(Br)C2=C1N SCHJLAFNBDGWJN-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 3
- 102000003915 DNA Topoisomerases Human genes 0.000 description 3
- 108090000323 DNA Topoisomerases Proteins 0.000 description 3
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 3
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 3
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- 101150112743 HSPA5 gene Proteins 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 108091005682 Receptor kinases Proteins 0.000 description 3
- 108091006627 SLC12A9 Proteins 0.000 description 3
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- OHNBIIZWIUBGTK-NYPSMHOZSA-N cid_23581792 Chemical compound O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 OHNBIIZWIUBGTK-NYPSMHOZSA-N 0.000 description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 description 3
- 101150028578 grp78 gene Proteins 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 150000002476 indolines Chemical class 0.000 description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 231100000782 microtubule inhibitor Toxicity 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 238000002638 palliative care Methods 0.000 description 3
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 3
- 229960000639 pazopanib Drugs 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 108020005087 unfolded proteins Proteins 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- FOVRGQUEGRCWPD-UHFFFAOYSA-N (5aR)-9t-beta-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(OC3C(C(O)C(O)C(CO)O3)O)C3C2C(OC3)=O)=C1 FOVRGQUEGRCWPD-UHFFFAOYSA-N 0.000 description 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 2
- YIOGOBYCEZTHTF-UHFFFAOYSA-N 1-(5-bromo-2,3-dihydroindol-1-yl)-2-phenylethanone Chemical compound C1CC2=CC(Br)=CC=C2N1C(=O)CC1=CC=CC=C1 YIOGOBYCEZTHTF-UHFFFAOYSA-N 0.000 description 2
- VBFLRIDZPBHHFD-UHFFFAOYSA-N 1-[5-(4-amino-7-iodofuro[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=C(I)C=2OC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F VBFLRIDZPBHHFD-UHFFFAOYSA-N 0.000 description 2
- KHXRLOSMYQPADV-UHFFFAOYSA-N 1-ethyl-3-iodopyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(CC)N=C(I)C2=C1N KHXRLOSMYQPADV-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LGZRIKTZAOPKET-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridin-3-amine Chemical group N1=CC=C2C(N)=NNC2=C1 LGZRIKTZAOPKET-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- AMPNBNGNPLXMOP-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)acetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1C AMPNBNGNPLXMOP-UHFFFAOYSA-N 0.000 description 2
- KUMFVKULPVCPOV-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydroindol-1-yl]ethanone Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N(CC2)C(=O)CC=3C(=CC=C(F)C=3)F)C2=C1 KUMFVKULPVCPOV-UHFFFAOYSA-N 0.000 description 2
- FKCRTRYQHZHXES-UHFFFAOYSA-N 2-(2,5-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC=C1F FKCRTRYQHZHXES-UHFFFAOYSA-N 0.000 description 2
- RUSCTNYOPQOXDJ-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)acetic acid Chemical compound CC1=CC=C(C)C(CC(O)=O)=C1 RUSCTNYOPQOXDJ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- JHILBAAZZQSBAI-UHFFFAOYSA-N 2-(2-fluoro-3-methylphenyl)acetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1F JHILBAAZZQSBAI-UHFFFAOYSA-N 0.000 description 2
- RPTRFSADOICSSK-UHFFFAOYSA-N 2-(2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1F RPTRFSADOICSSK-UHFFFAOYSA-N 0.000 description 2
- RZWGTXHSYZGXKF-UHFFFAOYSA-N 2-(2-methylphenyl)acetic acid Chemical compound CC1=CC=CC=C1CC(O)=O RZWGTXHSYZGXKF-UHFFFAOYSA-N 0.000 description 2
- HDNBKTWQBJJYPD-UHFFFAOYSA-N 2-(3,5-dimethylphenyl)acetic acid Chemical compound CC1=CC(C)=CC(CC(O)=O)=C1 HDNBKTWQBJJYPD-UHFFFAOYSA-N 0.000 description 2
- LBGHWXGWKTZILK-UHFFFAOYSA-N 2-(3-chloro-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1F LBGHWXGWKTZILK-UHFFFAOYSA-N 0.000 description 2
- WGODGMOMOMNTRN-UHFFFAOYSA-N 2-(3-chloro-4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(Cl)=C1 WGODGMOMOMNTRN-UHFFFAOYSA-N 0.000 description 2
- GFLQMGYDUPLXHZ-UHFFFAOYSA-N 2-(3-chloro-5-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(Cl)=C1 GFLQMGYDUPLXHZ-UHFFFAOYSA-N 0.000 description 2
- ZESQUNYKCICBQB-UHFFFAOYSA-N 2-(3-fluoro-2-methylphenyl)acetic acid Chemical compound CC1=C(F)C=CC=C1CC(O)=O ZESQUNYKCICBQB-UHFFFAOYSA-N 0.000 description 2
- GDUUQFGFHKTVEB-UHFFFAOYSA-N 2-(3-fluoro-5-methylphenyl)acetic acid Chemical compound CC1=CC(F)=CC(CC(O)=O)=C1 GDUUQFGFHKTVEB-UHFFFAOYSA-N 0.000 description 2
- YEAUYVGUXSZCFI-UHFFFAOYSA-N 2-(3-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1 YEAUYVGUXSZCFI-UHFFFAOYSA-N 0.000 description 2
- YXVVDWURKALCCT-UHFFFAOYSA-N 2-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)ethanol Chemical compound NC1=NC=NC2=C1C(I)=NN2CCO YXVVDWURKALCCT-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NRVPVUKWJYSNTO-UHFFFAOYSA-N 3-bromothieno[3,2-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1C(Br)=CS2 NRVPVUKWJYSNTO-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QGPYXNYRUAFOHC-UHFFFAOYSA-N 5-bromo-4-chloro-7-methylpyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2N(C)C=C(Br)C2=C1Cl QGPYXNYRUAFOHC-UHFFFAOYSA-N 0.000 description 2
- XIGNYVXBEMTBEM-UHFFFAOYSA-N 5-bromothieno[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C(Br)=CS2 XIGNYVXBEMTBEM-UHFFFAOYSA-N 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 2
- 229940126638 Akt inhibitor Drugs 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 2
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- 229960002563 disulfiram Drugs 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZYXBIOIYWUIXSM-UHFFFAOYSA-N furo[2,3-c]pyridine Chemical compound C1=NC=C2OC=CC2=C1 ZYXBIOIYWUIXSM-UHFFFAOYSA-N 0.000 description 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000018925 gastrointestinal mucositis Diseases 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229950002736 marizomib Drugs 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 2
- 229930192524 radicicol Natural products 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000021014 regulation of cell growth Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 2
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CDVJTLBCDOKHBL-UHFFFAOYSA-N tert-butyl 4-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=NC=NC(Cl)=C2C(Br)=C1 CDVJTLBCDOKHBL-UHFFFAOYSA-N 0.000 description 2
- ZQJJBLUZFZVTMK-UHFFFAOYSA-N tert-butyl 5-(2-cyano-3-fluorophenyl)-2,3-dihydroindole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)CCC2=CC=1C1=CC=CC(F)=C1C#N ZQJJBLUZFZVTMK-UHFFFAOYSA-N 0.000 description 2
- DGYDOOSQZBXHPK-UHFFFAOYSA-N tert-butyl 5-(3-amino-1-methylindazol-4-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C1=C2N(C(=O)OC(C)(C)C)CCC2=CC(C2=C3C(N)=NN(C3=CC=C2)C)=C1 DGYDOOSQZBXHPK-UHFFFAOYSA-N 0.000 description 2
- RUJABANXSPUGET-UHFFFAOYSA-N tert-butyl 5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C12=C(N)N=CN=C2N(C)N=C1C1=CC=C(N(CC2)C(=O)OC(C)(C)C)C2=C1 RUJABANXSPUGET-UHFFFAOYSA-N 0.000 description 2
- UOCVSZYBRMGQOL-UHFFFAOYSA-N tert-butyl 5-bromo-2,3-dihydroindole-1-carboxylate Chemical compound BrC1=CC=C2N(C(=O)OC(C)(C)C)CCC2=C1 UOCVSZYBRMGQOL-UHFFFAOYSA-N 0.000 description 2
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 2
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical compound N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- VSJKWCGYPAHWDS-HXUWFJFHSA-N (r)-camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-HXUWFJFHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TVCVZPPTRJJNOP-UHFFFAOYSA-N 1,2-dihydropyridine-2-carboxylic acid Chemical compound OC(=O)C1NC=CC=C1 TVCVZPPTRJJNOP-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- DDTZNSOMVMYKHA-UHFFFAOYSA-N 1-(1-acetyl-2,3-dihydroindol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2N(C(=O)C)CCC2=C1 DDTZNSOMVMYKHA-UHFFFAOYSA-N 0.000 description 1
- YIZXFZVLAQOAOS-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-2-phenylethanone Chemical compound C1CC2=CC=CC=C2N1C(=O)CC1=CC=CC=C1 YIZXFZVLAQOAOS-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PTOYIBJRFUYBLJ-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(2-methoxyphenyl)ethanone Chemical class COC1=CC=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)N=3)C=C2CC1 PTOYIBJRFUYBLJ-UHFFFAOYSA-N 0.000 description 1
- BDBSRJJIANRRCC-UHFFFAOYSA-N 1-[5-(4-amino-1-methylpyrazolo[3,4-d]pyrimidin-3-yl)-2,3-dihydroindol-1-yl]-2-(3-methoxyphenyl)ethanone Chemical class COC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)N=2)=C1 BDBSRJJIANRRCC-UHFFFAOYSA-N 0.000 description 1
- PBGDYMQPNUECPR-UHFFFAOYSA-N 1-[5-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindol-1-yl]-2-phenylethanone Chemical compound C1=2C(N)=NC=C(I)C=2SC=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC=C1 PBGDYMQPNUECPR-UHFFFAOYSA-N 0.000 description 1
- RLCMPEIQSYJWHP-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(2-methoxyphenyl)ethanone Chemical class COC1=CC=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 RLCMPEIQSYJWHP-UHFFFAOYSA-N 0.000 description 1
- NSTSANFOMJOPFU-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-methoxyphenyl)ethanone Chemical class COC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=C1 NSTSANFOMJOPFU-UHFFFAOYSA-N 0.000 description 1
- NEIQAGHTFXGFSZ-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1CC(=O)N1C2=CC=C(C=3C4=C(N)N=CN=C4N(C)C=3)C=C2CC1 NEIQAGHTFXGFSZ-UHFFFAOYSA-N 0.000 description 1
- HYTDBDSCJFRONV-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(6-chloropyridin-2-yl)ethanone Chemical class C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(Cl)=N1 HYTDBDSCJFRONV-UHFFFAOYSA-N 0.000 description 1
- VYZYOJULVVGQRS-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(6-methylpyridin-2-yl)ethanone Chemical class CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C)C=2)=N1 VYZYOJULVVGQRS-UHFFFAOYSA-N 0.000 description 1
- GIULQYUVYNZAJN-UHFFFAOYSA-N 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-chloro-2,3-dihydroindol-1-yl]-2-[6-(trifluoromethyl)pyridin-2-yl]ethanone Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C(=C1CC2)Cl)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=N1 GIULQYUVYNZAJN-UHFFFAOYSA-N 0.000 description 1
- FIRQKUMUQHTIBS-UHFFFAOYSA-N 1-[5-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-(3-methylphenyl)ethanone Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3SC=2)=C1 FIRQKUMUQHTIBS-UHFFFAOYSA-N 0.000 description 1
- PRDSGLNLHGOUNK-UHFFFAOYSA-N 1-[5-[4-amino-7-(oxetan-3-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydroindol-1-yl]-2-(2,5-difluorophenyl)ethanone Chemical compound C1=2C(N)=NC=NC=2N(C2COC2)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC(F)=CC=C1F PRDSGLNLHGOUNK-UHFFFAOYSA-N 0.000 description 1
- PJGJXRVDWFQXCT-UHFFFAOYSA-N 1-bromo-4-chloropyrrolo[2,3-d]pyrimidine Chemical compound C1=CN=C2C1=C(N=CN2Br)Cl PJGJXRVDWFQXCT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- RDJANRMVIYMEGG-UHFFFAOYSA-N 1-oxacyclotetradeca-5,7,11,13-tetraene-4,10-dione Chemical compound O1C=CC=CC(CC=CC=CC(CC1)=O)=O RDJANRMVIYMEGG-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 1
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical compound C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 1
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 description 1
- PFKSLFZFBCIJOI-UHFFFAOYSA-N 2,2-difluoro-2-phenylacetic acid Chemical compound OC(=O)C(F)(F)C1=CC=CC=C1 PFKSLFZFBCIJOI-UHFFFAOYSA-N 0.000 description 1
- OJHWPOJTJKJBLA-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-benzimidazole Chemical compound C1C=CC=C2NCNC21 OJHWPOJTJKJBLA-UHFFFAOYSA-N 0.000 description 1
- RKXNLMZRERZATJ-UHFFFAOYSA-N 2,3-dihydro-1H-indole Chemical compound C1=CC=C2NCCC2=C1.C1=CC=C2NCCC2=C1 RKXNLMZRERZATJ-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- HHVKNKDKNBABCU-UHFFFAOYSA-N 2-(2,3,5-trifluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(F)=C1F HHVKNKDKNBABCU-UHFFFAOYSA-N 0.000 description 1
- QPKZIGHNRLZBCL-UHFFFAOYSA-N 2-(2,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1F QPKZIGHNRLZBCL-UHFFFAOYSA-N 0.000 description 1
- HENNVWWQJGUCAH-UHFFFAOYSA-N 2-(3-chloro-2,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(Cl)=C1F HENNVWWQJGUCAH-UHFFFAOYSA-N 0.000 description 1
- GYMCMMPTJVTSRY-UHFFFAOYSA-N 2-(3-chlorophenyl)-1-(5-thieno[3,2-c]pyridin-3-yl-2,3-dihydroindol-1-yl)ethanone Chemical compound ClC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=CN=CC=C3SC=2)=C1 GYMCMMPTJVTSRY-UHFFFAOYSA-N 0.000 description 1
- XHPMSYWCKADLPJ-UHFFFAOYSA-N 2-(3-fluorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(F)=C1 XHPMSYWCKADLPJ-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- GXXXUZIRGXYDFP-UHFFFAOYSA-N 2-(4-methylphenyl)acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1 GXXXUZIRGXYDFP-UHFFFAOYSA-N 0.000 description 1
- NOKLOLLCDCEFAK-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC=C1F NOKLOLLCDCEFAK-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- LQIBHDUPSIQRPV-UHFFFAOYSA-N 2-[3-fluoro-5-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(C(F)(F)F)=C1 LQIBHDUPSIQRPV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IGOYNRWLWHWAQO-UHFFFAOYSA-N 2-[[2-[(2-azaniumylacetyl)amino]-3-phenylpropanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)C(NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-UHFFFAOYSA-N 0.000 description 1
- FICQFRCPSFCFBY-UHFFFAOYSA-N 2-[bis(methylsulfanyl)methylidene]propanedinitrile Chemical compound CSC(SC)=C(C#N)C#N FICQFRCPSFCFBY-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- VIBOGIYPPWLDTI-UHFFFAOYSA-N 2-naphthylacetic acid Chemical compound C1=CC=CC2=CC(CC(=O)O)=CC=C21 VIBOGIYPPWLDTI-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- OFQDFQBVBOCARA-UHFFFAOYSA-N 3-(2,3-dihydro-1h-indol-5-yl)furo[3,2-c]pyridin-4-amine Chemical compound C1=C2NCCC2=CC(C2=COC=3C=CN=C(C2=3)N)=C1 OFQDFQBVBOCARA-UHFFFAOYSA-N 0.000 description 1
- HQLSDXBIWNTZNE-UHFFFAOYSA-N 3-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)azetidine-1-carboxylic acid Chemical compound BrC1=CN(C=2N=CN=C(C21)Cl)C2CN(C2)C(=O)O HQLSDXBIWNTZNE-UHFFFAOYSA-N 0.000 description 1
- BRKRVHFCIWULMB-UHFFFAOYSA-N 3-[4-amino-3-[1-(2-phenylacetyl)-2,3-dihydroindol-5-yl]thieno[3,2-c]pyridin-7-yl]benzaldehyde Chemical compound C1=2SC=C(C=3C=C4CCN(C4=CC=3)C(=O)CC=3C=CC=CC=3)C=2C(N)=NC=C1C1=CC=CC(C=O)=C1 BRKRVHFCIWULMB-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 description 1
- HYJVYOWKYPNSTK-UHFFFAOYSA-N 3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(O)C(O)=O)NC(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UHFFFAOYSA-N 0.000 description 1
- GZQVGSRUUTUJNG-UHFFFAOYSA-N 3-bromo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(Br)=C12 GZQVGSRUUTUJNG-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- PMHOWXRNJXWYIP-UHFFFAOYSA-N 4,5-dihydrooxazaphosphole Chemical class C1CP=NO1 PMHOWXRNJXWYIP-UHFFFAOYSA-N 0.000 description 1
- QCJPGIFKFKZXAQ-UHFFFAOYSA-N 4-(3-fluoroazetidin-1-yl)piperidine Chemical compound C1C(F)CN1C1CCNCC1 QCJPGIFKFKZXAQ-UHFFFAOYSA-N 0.000 description 1
- ISGIRHVNVLAEFV-UHFFFAOYSA-N 4-[2-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)ethyl]morpholine Chemical compound C1=C(Br)C=2C(Cl)=NC=NC=2N1CCN1CCOCC1 ISGIRHVNVLAEFV-UHFFFAOYSA-N 0.000 description 1
- BJGDLOLPALCTJQ-UHFFFAOYSA-N 4-chloro-7-methylpyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2N(C)C=CC2=C1Cl BJGDLOLPALCTJQ-UHFFFAOYSA-N 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- UCFAPIQEJXINGM-UHFFFAOYSA-N 5-(2,3-dihydro-1h-indol-5-yl)-7-methylpyrrolo[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C12=C(N)N=CN=C2N(C)C=C1C1=CC=C(NCC2)C2=C1 UCFAPIQEJXINGM-UHFFFAOYSA-N 0.000 description 1
- ZYOHYGQNRQMVMG-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1h-indole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(NCC2)C2=C1 ZYOHYGQNRQMVMG-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- XPVLPKRYRZAKAU-UHFFFAOYSA-N 5-bromo-4-chloro-7-(methoxymethyl)pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2N(COC)C=C(Br)C2=C1Cl XPVLPKRYRZAKAU-UHFFFAOYSA-N 0.000 description 1
- IKCKRHCJPVDELP-UHFFFAOYSA-N 5-bromo-4-chlorothieno[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(Br)=CS2 IKCKRHCJPVDELP-UHFFFAOYSA-N 0.000 description 1
- OELRHZDCGYBXAG-UHFFFAOYSA-N 5-bromo-7-(methoxymethyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(COC)C=C(Br)C2=C1N OELRHZDCGYBXAG-UHFFFAOYSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- DGCBTMCXHXNPHH-UHFFFAOYSA-N 5-oxoheptanal Chemical compound CCC(=O)CCCC=O DGCBTMCXHXNPHH-UHFFFAOYSA-N 0.000 description 1
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- NOALBODUTGHVMC-UHFFFAOYSA-N C1=C2N(C(O)=O)CCC2=CC(C2=COC=3C=CN=C(C2=3)N)=C1 Chemical compound C1=C2N(C(O)=O)CCC2=CC(C2=COC=3C=CN=C(C2=3)N)=C1 NOALBODUTGHVMC-UHFFFAOYSA-N 0.000 description 1
- DWFIXFIASDOKAX-UHFFFAOYSA-N C1C=C2C(=CC=NC2(N)Br)O1 Chemical compound C1C=C2C(=CC=NC2(N)Br)O1 DWFIXFIASDOKAX-UHFFFAOYSA-N 0.000 description 1
- TVJOUGWOSYBSLA-UHFFFAOYSA-N C1CN(C2=C1C=C(C=C2)C3=NC(=C4C=CNC4=N3)N)C(=O)CC5=C(C(=CC(=C5)F)F)F Chemical compound C1CN(C2=C1C=C(C=C2)C3=NC(=C4C=CNC4=N3)N)C(=O)CC5=C(C(=CC(=C5)F)F)F TVJOUGWOSYBSLA-UHFFFAOYSA-N 0.000 description 1
- WKXBKTGJLVZXPK-UHFFFAOYSA-N CC1=CC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3)C4=CNC5=NC=NC(=C45)N Chemical compound CC1=CC(=CC=C1)CC(=O)N2CCC3=C2C=CC(=C3)C4=CNC5=NC=NC(=C45)N WKXBKTGJLVZXPK-UHFFFAOYSA-N 0.000 description 1
- GMSSLJMYKIRZGH-UHFFFAOYSA-N CC1=CN=CC2=C1OC=C2C3=CC4=C(C=C3)N(CC4)C(=O)CC5=C(C=CC(=C5)F)F Chemical compound CC1=CN=CC2=C1OC=C2C3=CC4=C(C=C3)N(CC4)C(=O)CC5=C(C=CC(=C5)F)F GMSSLJMYKIRZGH-UHFFFAOYSA-N 0.000 description 1
- CYVJPENAINPXNA-UHFFFAOYSA-N CCOC(=O)N1CCC2=C1C=CC(=C2)C3=C(C(=CC=C3)F)C#N Chemical compound CCOC(=O)N1CCC2=C1C=CC(=C2)C3=C(C(=CC=C3)F)C#N CYVJPENAINPXNA-UHFFFAOYSA-N 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 101710156077 DNA damage-inducible transcript 3 protein Proteins 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101710196292 Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- 244000050403 Iris x germanica Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001147844 Streptomyces verticillus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 1
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- ICBJPNRJVTUWOE-WDEREUQCSA-N [(1S,2R)-2-hydroxy-3-[(2-methylpropan-2-yl)oxy]-3-oxo-1-phenylpropyl]carbamic acid Chemical compound CC(C)(C)OC(=O)[C@H](O)[C@@H](NC(O)=O)C1=CC=CC=C1 ICBJPNRJVTUWOE-WDEREUQCSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- UTKBLLDLHPDWDU-ODZAUARKSA-N acetic acid;(z)-but-2-enedioic acid Chemical class CC(O)=O.OC(=O)\C=C/C(O)=O UTKBLLDLHPDWDU-ODZAUARKSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- UETQVDZZPKAQIC-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl.Cl UETQVDZZPKAQIC-UHFFFAOYSA-N 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005831 deiodination reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- KQGXYVJZOMKLSA-UHFFFAOYSA-N furo[2,3-d]pyrimidine Chemical compound N1=CN=C2OC=CC2=C1 KQGXYVJZOMKLSA-UHFFFAOYSA-N 0.000 description 1
- IWMQAUYDCYPLFK-UHFFFAOYSA-N furo[3,2-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1C=CO2 IWMQAUYDCYPLFK-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WFFQYWAAEWLHJC-UHFFFAOYSA-N mercaptopurine hydrate Chemical compound O.S=C1NC=NC2=C1NC=N2 WFFQYWAAEWLHJC-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- JETOHTFRRRLDMU-UHFFFAOYSA-N tert-butyl 3-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1N1C2=NC=NC(N)=C2C(Br)=C1 JETOHTFRRRLDMU-UHFFFAOYSA-N 0.000 description 1
- OSZKLJLCQXQUIT-UHFFFAOYSA-N tert-butyl 3-(5-bromo-4-chloropyrrolo[2,3-d]pyrimidin-7-yl)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1N1C2=NC=NC(Cl)=C2C(Br)=C1 OSZKLJLCQXQUIT-UHFFFAOYSA-N 0.000 description 1
- KKFYJDCTNLJUMC-UHFFFAOYSA-N tert-butyl 3-[4-amino-5-[1-[2-(3-methylphenyl)acetyl]-2,3-dihydroindol-5-yl]pyrrolo[2,3-d]pyrimidin-7-yl]azetidine-1-carboxylate Chemical compound CC1=CC=CC(CC(=O)N2C3=CC=C(C=C3CC2)C=2C3=C(N)N=CN=C3N(C3CN(C3)C(=O)OC(C)(C)C)C=2)=C1 KKFYJDCTNLJUMC-UHFFFAOYSA-N 0.000 description 1
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- SKNDSDIUUNFNKM-UHFFFAOYSA-N tert-butyl 4-[4-amino-3-[1-(2-phenylacetyl)-2,3-dihydroindol-5-yl]thieno[3,2-c]pyridin-7-yl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C=3SC=C(C=3C(N)=NC=2)C=2C=C3CCN(C3=CC=2)C(=O)CC=2C=CC=CC=2)=C1 SKNDSDIUUNFNKM-UHFFFAOYSA-N 0.000 description 1
- QOQCYZQJKYVWAR-UHFFFAOYSA-N tert-butyl 4-[4-amino-5-[1-[2-(2,5-difluorophenyl)acetyl]-2,3-dihydroindol-5-yl]pyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C2=NC=NC(N)=C2C(C=2C=C3CCN(C3=CC=2)C(=O)CC=2C(=CC=C(F)C=2)F)=C1 QOQCYZQJKYVWAR-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- LAWWHRMTYRKZDJ-UHFFFAOYSA-N tert-butyl 5-(4-aminothieno[3,2-c]pyridin-3-yl)-2,3-dihydroindole-1-carboxylate Chemical compound C1=NC(N)=C2C(C=3C=C4CCN(C4=CC=3)C(=O)OC(C)(C)C)=CSC2=C1 LAWWHRMTYRKZDJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- YASDAMSCJQDYKJ-UHFFFAOYSA-N tricos-7-ene-2,5,15,18,21-pentone Chemical compound CCC(=O)CCC(=O)CCC(=O)CCCCCCC=CCC(=O)CCC(C)=O YASDAMSCJQDYKJ-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31747610P | 2010-03-25 | 2010-03-25 | |
| US61/317,476 | 2010-03-25 | ||
| US35286310P | 2010-06-09 | 2010-06-09 | |
| US61/352,863 | 2010-06-09 | ||
| US38148010P | 2010-09-10 | 2010-09-10 | |
| US61/381,480 | 2010-09-10 | ||
| US38815110P | 2010-09-30 | 2010-09-30 | |
| US61/388,151 | 2010-09-30 | ||
| US41906810P | 2010-12-02 | 2010-12-02 | |
| US61/419,068 | 2010-12-02 | ||
| PCT/US2011/029511 WO2011119663A1 (en) | 2010-03-25 | 2011-03-23 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534902A JP2013534902A (ja) | 2013-09-09 |
| JP2013534902A5 JP2013534902A5 (OSRAM) | 2014-05-08 |
| JP5876031B2 true JP5876031B2 (ja) | 2016-03-02 |
Family
ID=46160738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501421A Expired - Fee Related JP5876031B2 (ja) | 2010-03-25 | 2011-03-23 | 化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120077828A1 (OSRAM) |
| EP (1) | EP2549868B1 (OSRAM) |
| JP (1) | JP5876031B2 (OSRAM) |
| KR (1) | KR101676077B1 (OSRAM) |
| CN (1) | CN102917588B (OSRAM) |
| AR (1) | AR080792A1 (OSRAM) |
| AU (1) | AU2011232516B2 (OSRAM) |
| EA (1) | EA022325B1 (OSRAM) |
| ES (1) | ES2530955T3 (OSRAM) |
| IL (1) | IL222120A (OSRAM) |
| MX (1) | MX2012011045A (OSRAM) |
| SG (1) | SG183954A1 (OSRAM) |
| TW (1) | TW201202241A (OSRAM) |
| UY (1) | UY33288A (OSRAM) |
| WO (1) | WO2011119663A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| US20140227289A1 (en) * | 2011-05-13 | 2014-08-14 | Stephen Michael Cohen | Compounds and methods for treating insulin resistance syndrome |
| EP3495368B1 (en) | 2011-07-19 | 2023-05-31 | Merck Sharp & Dohme B.V. | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
| CN104918934B (zh) | 2013-01-18 | 2017-12-22 | 霍夫曼-拉罗奇有限公司 | 3‑取代的吡唑及其作为dlk抑制剂的用途 |
| EA027811B1 (ru) * | 2013-04-04 | 2017-09-29 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK |
| TWI482757B (zh) * | 2013-10-07 | 2015-05-01 | Luminescence Technology Corp | Ｖｅｇｆ－２／３受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途 |
| WO2015056180A1 (en) * | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| JP2017507967A (ja) * | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤として作用する化合物 |
| US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
| TW201618772A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物 |
| HUE050706T2 (hu) * | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
| CA2967125C (en) | 2014-11-14 | 2022-10-25 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| WO2016126026A2 (ko) * | 2015-02-04 | 2016-08-11 | 서울대학교병원 | 당뇨병 치료 조성물 및 이의 용도 |
| SI3317281T1 (sl) | 2015-07-02 | 2020-08-31 | Acerta Pharma B.V. | Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida |
| WO2017046739A1 (en) * | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
| TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| CN113549110B (zh) * | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| SG11201808878UA (en) * | 2016-04-15 | 2018-11-29 | Cancer Research Tech Ltd | Heterocyclic compounds as ret kinase inhibitors |
| US11026945B2 (en) * | 2016-04-29 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
| EP3472133B1 (en) | 2016-06-13 | 2023-10-11 | Ramot at Tel-Aviv University Ltd. | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins |
| CN109311894B (zh) | 2016-06-21 | 2022-03-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物 |
| JP2019521166A (ja) * | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤としてのイソキノリン誘導体 |
| WO2018055578A1 (en) * | 2016-09-22 | 2018-03-29 | The University Of Hong Kong | Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases |
| EP3573608A1 (en) | 2017-01-30 | 2019-12-04 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| CN106974910B (zh) * | 2017-03-02 | 2019-11-12 | 深圳大学 | 含索拉非尼和gsk2656157的药物组合物及用途 |
| CN106963769B (zh) * | 2017-03-03 | 2019-10-25 | 深圳大学 | 含pi3k抑制剂和perk抑制剂的药物组合物及其应用 |
| FI3593817T3 (fi) * | 2017-03-06 | 2025-02-05 | Tsubota Lab Inc | Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä |
| DK3448859T3 (da) * | 2017-03-20 | 2019-09-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer |
| WO2019021208A1 (en) * | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| CN108003163B (zh) * | 2017-11-30 | 2020-11-24 | 武汉九州钰民医药科技有限公司 | 用作激酶抑制剂的吡唑并嘧啶类化合物及其应用 |
| CN111100130B (zh) * | 2018-10-29 | 2022-07-15 | 四川大学 | 4-氨基吡咯并嘧啶衍生物及其制备方法和用途 |
| CN111213632B (zh) * | 2019-11-19 | 2022-03-01 | 长春中医药大学 | 动物药环氧树脂标本制作方法 |
| AU2021289345A1 (en) | 2020-06-08 | 2023-01-19 | Halia Therapeutics, Inc. | Inhibitors of NEK7 kinase |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240382488A1 (en) | 2021-03-29 | 2024-11-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2023034236A1 (en) * | 2021-08-31 | 2023-03-09 | Wisconsin Alumni Research Foundation | Deuterated inhibitors of rip kinases |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| PT1761528E (pt) * | 2004-06-11 | 2008-04-15 | Japan Tobacco Inc | Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro |
| US20080255184A1 (en) * | 2005-11-04 | 2008-10-16 | Smithkline Beecham Corporation | Thienopyridine B-Raf Kinase Inhibitors |
| AU2007272330A1 (en) * | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| WO2009151621A1 (en) | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
| ES2536730T3 (es) * | 2008-09-19 | 2015-05-28 | Nerviano Medical Sciences S.R.L. | Derivados de 3,4-dihidro-2H-pirrolo[1,2-a]pirazin-1-ona |
-
2011
- 2011-03-22 UY UY0001033288A patent/UY33288A/es not_active Application Discontinuation
- 2011-03-23 SG SG2012066379A patent/SG183954A1/en unknown
- 2011-03-23 KR KR1020127027705A patent/KR101676077B1/ko not_active Expired - Fee Related
- 2011-03-23 EA EA201290952A patent/EA022325B1/ru not_active IP Right Cessation
- 2011-03-23 AR ARP110100955A patent/AR080792A1/es not_active Application Discontinuation
- 2011-03-23 JP JP2013501421A patent/JP5876031B2/ja not_active Expired - Fee Related
- 2011-03-23 ES ES11760102T patent/ES2530955T3/es active Active
- 2011-03-23 MX MX2012011045A patent/MX2012011045A/es active IP Right Grant
- 2011-03-23 CN CN201180025962.7A patent/CN102917588B/zh not_active Expired - Fee Related
- 2011-03-23 WO PCT/US2011/029511 patent/WO2011119663A1/en not_active Ceased
- 2011-03-23 US US13/069,569 patent/US20120077828A1/en not_active Abandoned
- 2011-03-23 AU AU2011232516A patent/AU2011232516B2/en not_active Ceased
- 2011-03-23 TW TW100109800A patent/TW201202241A/zh unknown
- 2011-03-23 EP EP11760102.1A patent/EP2549868B1/en active Active
-
2012
- 2012-09-24 IL IL222120A patent/IL222120A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011232516A1 (en) | 2012-10-04 |
| MX2012011045A (es) | 2012-11-16 |
| AR080792A1 (es) | 2012-05-09 |
| EP2549868B1 (en) | 2015-01-07 |
| AU2011232516B2 (en) | 2014-08-07 |
| CN102917588B (zh) | 2014-10-08 |
| US20120077828A1 (en) | 2012-03-29 |
| WO2011119663A8 (en) | 2012-10-26 |
| UY33288A (es) | 2011-10-31 |
| JP2013534902A (ja) | 2013-09-09 |
| WO2011119663A1 (en) | 2011-09-29 |
| EP2549868A1 (en) | 2013-01-30 |
| SG183954A1 (en) | 2012-10-30 |
| ES2530955T3 (es) | 2015-03-09 |
| KR101676077B1 (ko) | 2016-11-14 |
| EA201290952A1 (ru) | 2013-04-30 |
| EP2549868A4 (en) | 2013-08-07 |
| KR20130018272A (ko) | 2013-02-20 |
| EA022325B1 (ru) | 2015-12-30 |
| CN102917588A (zh) | 2013-02-06 |
| AU2011232516A8 (en) | 2012-12-13 |
| IL222120A (en) | 2015-09-24 |
| TW201202241A (en) | 2012-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5876031B2 (ja) | 化合物 | |
| US8598156B2 (en) | Chemical compounds | |
| JP6430390B2 (ja) | Ｔ７９０ｍを含むｅｇｆｒ変異体の阻害剤としてのアミノピリミジン化合物 | |
| JP5864545B2 (ja) | インドール | |
| JP5889875B2 (ja) | アザインダゾール | |
| WO2015056180A1 (en) | Indoline derivatives as inhibitors of perk | |
| JP2014504269A (ja) | 化学化合物 | |
| JP5964426B2 (ja) | 脂肪酸シンターゼ阻害剤 | |
| WO2018015879A1 (en) | Isoquinoline derivatives as perk inhibitors | |
| KR20120133386A (ko) | 지방산 신타제 억제제로서의 트리아졸론 | |
| WO2010120854A1 (en) | Chemical compounds | |
| JP2013508461A (ja) | 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール | |
| JP2013512245A (ja) | 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール | |
| WO2019053617A1 (en) | CHEMICAL COMPOUNDS | |
| JP5554833B2 (ja) | Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体 | |
| WO2013096153A1 (en) | Chemical compounds | |
| ES2651331T3 (es) | Inhibidores de la sintasa de ácidos grasos | |
| HK1238646A1 (en) | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants | |
| HK1238646B (en) | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140324 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150427 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150626 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160120 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5876031 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |